AU2020215150B8 - Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders - Google Patents
Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders Download PDFInfo
- Publication number
- AU2020215150B8 AU2020215150B8 AU2020215150A AU2020215150A AU2020215150B8 AU 2020215150 B8 AU2020215150 B8 AU 2020215150B8 AU 2020215150 A AU2020215150 A AU 2020215150A AU 2020215150 A AU2020215150 A AU 2020215150A AU 2020215150 B8 AU2020215150 B8 AU 2020215150B8
- Authority
- AU
- Australia
- Prior art keywords
- amount
- less
- psilocybin
- psilocin
- receptor agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025203049A AU2025203049A1 (en) | 2019-01-30 | 2025-04-30 | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799010P | 2019-01-30 | 2019-01-30 | |
| US201962798998P | 2019-01-30 | 2019-01-30 | |
| US62/798,998 | 2019-01-30 | ||
| US62/799,010 | 2019-01-30 | ||
| PCT/IB2020/000052 WO2020157569A1 (en) | 2019-01-30 | 2020-01-29 | Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203049A Division AU2025203049A1 (en) | 2019-01-30 | 2025-04-30 | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2020215150A1 AU2020215150A1 (en) | 2021-09-09 |
| AU2020215150B2 AU2020215150B2 (en) | 2025-02-06 |
| AU2020215150B8 true AU2020215150B8 (en) | 2025-07-03 |
| AU2020215150A8 AU2020215150A8 (en) | 2025-07-03 |
Family
ID=71841404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020215150A Active AU2020215150B8 (en) | 2019-01-30 | 2020-01-29 | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| AU2025203049A Pending AU2025203049A1 (en) | 2019-01-30 | 2025-04-30 | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025203049A Pending AU2025203049A1 (en) | 2019-01-30 | 2025-04-30 | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20220096504A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3917537A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022523700A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210134313A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114040767A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020215150B8 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021014750A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127854A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285186A (cg-RX-API-DMAC7.html) |
| MA (1) | MA54877A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021009037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020157569A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311984A (en) | 2016-07-07 | 2024-06-01 | Hughes Howard Med Inst | Modified ligand-gated ion channels and methods of use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN111556751B (zh) | 2017-11-10 | 2024-07-12 | 霍华休斯医学研究院 | 经修饰的配体门控的离子通道及使用方法 |
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| US20210023052A1 (en) * | 2019-07-23 | 2021-01-28 | Caamtech Llc | Compositions containing toad secretion compounds |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス,インコーポレイテッド | カンナビジオールの経皮送達 |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| WO2021072530A1 (en) * | 2019-10-15 | 2021-04-22 | Tassili Life Sciences, Corp. | Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder. |
| US20230021957A1 (en) * | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| US20210220336A1 (en) * | 2020-01-22 | 2021-07-22 | Clexio Biosciences Ltd. | Topical detomidine formulations |
| AU2021215709A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| US20240277736A1 (en) * | 2020-04-17 | 2024-08-22 | Revive Therapeutics Ltd | Use of psilocybin in the treatment of neurological brain injury and migraines |
| AU2021267101B2 (en) | 2020-05-05 | 2024-03-28 | Universitätsspital Basel | MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2021243460A1 (en) * | 2020-06-03 | 2021-12-09 | Neonmind Biosciences Inc. | Method for weight loss with therapy |
| WO2022023812A1 (en) * | 2020-07-29 | 2022-02-03 | Diamond Therapeutics Inc. | Extended release 5-ht receptor agonists for neurological conditions |
| US20220062310A1 (en) * | 2020-09-03 | 2022-03-03 | Yale University | Psilocybin in patients with obsessive-compulsive disorder |
| US20230364115A1 (en) * | 2020-10-01 | 2023-11-16 | Mydecine Innovations Group Inc. | Novel psychedelic compositions, delivery systems and therapeutic uses thereof |
| WO2022079574A1 (en) * | 2020-10-12 | 2022-04-21 | Goodcap Pharmaceuticals Ltd. | Compositions for reducing inflammation to improve or maintain mental or physical health |
| WO2022094054A1 (en) * | 2020-10-28 | 2022-05-05 | Mydecine Innovations Group Inc. | Novel fungal compound formulations and their therapeutic methods of use |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022115798A2 (en) * | 2020-11-30 | 2022-06-02 | Wesana Health Inc. | Compositions and methods for treating migraine |
| WO2022115796A1 (en) * | 2020-11-30 | 2022-06-02 | Wesana Health Inc. | Compositions and methods for treating neurological conditions |
| CA3201913A1 (en) | 2020-12-09 | 2022-06-16 | Andrew R. Chadeayne | Dialkyl trytamines and their therapeutic uses |
| CA3113240C (en) | 2020-12-28 | 2023-09-05 | Psilo Scientific Ltd. | Transmucosal psychoactive alkaloid composition and preparation thereof |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US20220265601A1 (en) * | 2021-02-10 | 2022-08-25 | David Alan Heldreth, JR. | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| US20220370413A1 (en) * | 2021-03-06 | 2022-11-24 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| EP4304603A4 (en) * | 2021-03-08 | 2025-01-22 | Diamond Therapeutics Inc. | 5-ht receptor agonist titration |
| WO2022204323A1 (en) * | 2021-03-24 | 2022-09-29 | The Trustees Of Columbia University In The City Of New York | Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders |
| MX2023011326A (es) * | 2021-03-30 | 2023-10-03 | Compass Pathfinder Ltd | Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas. |
| KR20240006525A (ko) * | 2021-03-31 | 2024-01-15 | 라이프 씨에이치엔지 엘엘씨 | 환각제의 치료적 투여를 위한 경피 시스템, 제제 및 방법 |
| WO2022221554A2 (en) * | 2021-04-16 | 2022-10-20 | Callitas Health Inc. | Compositions and methods for delivery of psilocin and prodrugs thereof |
| WO2022221942A1 (en) * | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prevention of drug diversion |
| EP4329759A4 (en) * | 2021-04-30 | 2025-07-16 | Mind Medicine Inc | CRYSTALLINE FORMS OF LSD SALTS |
| EP4333979A4 (en) * | 2021-05-03 | 2025-01-15 | Mind Medicine, Inc. | Method of titrating dose of psychedelics |
| WO2022235514A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
| WO2022261058A1 (en) * | 2021-06-07 | 2022-12-15 | University Of Mississippi | Methods for the pulsed delivery of bioactive agents |
| US11801256B2 (en) | 2021-06-08 | 2023-10-31 | Universitätsspital Basel | Antidepressant-psilocybin co-treatment to assist psychotherapy |
| GB202109023D0 (en) * | 2021-06-23 | 2021-08-04 | Ldn Pharma Ltd | Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3 |
| US20240366638A1 (en) * | 2021-06-25 | 2024-11-07 | Synaptive Therapeutics Llc | Psilocybin analogs for treating psychological disorders |
| US20230064429A1 (en) | 2021-08-19 | 2023-03-02 | Mind Medicine, Inc. | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| US20230219955A1 (en) * | 2021-09-20 | 2023-07-13 | Betterlife Pharma Inc. | Lsd derivatives, synthesis & method for treatment of diseases and disorders |
| EP4408412A4 (en) * | 2021-09-30 | 2025-07-16 | ATAI Life Sciences AG | COMPOSITIONS AND METHODS FOR TREATING HEADACHES |
| WO2023086962A1 (en) * | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| US20250073207A1 (en) * | 2022-01-12 | 2025-03-06 | Eleusis Therapeutics Us, Inc. | Psilocin benzoate formulation for intravenous infusion |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| EP4499109A1 (en) * | 2022-03-25 | 2025-02-05 | Ojai Energetics PBC | Psychedelic compositions and methods for forming the same |
| EP4514831A4 (en) * | 2022-04-27 | 2026-06-17 | Hughes Howard Med Inst | Chemogenetic receptors and their manufacturing and use processes |
| EP4522165A1 (en) * | 2022-05-13 | 2025-03-19 | Reset Pharmaceuticals, Inc. | Administration of a psychedelic compound by subcutaneous injection |
| CA3247344A1 (en) | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| WO2023248222A1 (en) * | 2022-06-21 | 2023-12-28 | Technion Research & Development Foundation Limited | 5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders |
| US20240000795A1 (en) * | 2022-06-30 | 2024-01-04 | Terran Biosciences Inc. | Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators |
| US12344583B2 (en) | 2022-07-12 | 2025-07-01 | Lobe Sciences Ltd. | Solid psilocin salts |
| KR20250035567A (ko) * | 2022-07-12 | 2025-03-12 | 로브 사이언시즈 엘티디. | 안정된 실로신 염, 에스테르 및 접합체의 제조 및 이의 용도 |
| WO2024019908A1 (en) * | 2022-07-19 | 2024-01-25 | Lobe Sciences Ltd. | Serotonergic psychedelic agent for treating selective mutism |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024079648A1 (en) * | 2022-10-11 | 2024-04-18 | Sintalica S.R.L. | Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof |
| WO2024151625A1 (en) * | 2023-01-10 | 2024-07-18 | Georgetown University | Non-toxic plga compositions and methods of making and using same |
| CN121358470A (zh) * | 2023-02-23 | 2026-01-16 | 布莱特西德公司 | 用于调节g蛋白偶联受体的组合物和方法 |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| EP4739303A2 (en) * | 2023-07-03 | 2026-05-13 | EmpathBio, Inc. | Mdma enantiomer compositions and methods for modulating aggression response |
| WO2025024400A2 (en) * | 2023-07-21 | 2025-01-30 | 2A Biosciences, Inc. | Substituted tryptamines and uses thereof |
| WO2025040932A1 (en) * | 2023-08-21 | 2025-02-27 | Nechama Golan | Fully curing all mental diseases with the use of d-lysergic acid amide in different doses and time of treatment |
| WO2026068690A1 (en) * | 2024-09-27 | 2026-04-02 | Medichem, S.A. | Quetiapine long-acting injection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU36879A1 (cg-RX-API-DMAC7.html) | 1958-02-21 | |||
| US3192111A (en) | 1959-02-16 | 1965-06-29 | Sandoz Ltd | Method of inducing therapeutic tranquilization with psilocybin and psilocin |
| IL136023A0 (en) | 1999-05-14 | 2001-05-20 | Pfizer Prod Inc | 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine |
| CA2422730A1 (en) | 2000-09-19 | 2002-03-28 | Microbia, Inc. | Modulation of secondary metabolite production by zinc binuclear cluster proteins |
| US10738268B2 (en) | 2016-08-21 | 2020-08-11 | Insectergy, Llc | Cannabis nanoemulsion methods |
| US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| CA2537132A1 (en) | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Amorphous valganciclovir hydrochloride |
| US9408405B2 (en) * | 2003-10-03 | 2016-08-09 | Veijlen N.V. | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| WO2010123577A2 (en) | 2009-04-24 | 2010-10-28 | Galenea Corp. | Compositions and methods for evaluating cognitive deficits |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| EP2884888A4 (en) | 2012-08-16 | 2016-04-20 | Ginger Io Inc | METHOD FOR MODELING BEHAVIORAL AND HEALTH CHANGES |
| CN103778171A (zh) | 2012-10-24 | 2014-05-07 | I-昂索夫特有限公司 | 利用健康指数的健康媒体推荐系统 |
| WO2014140925A2 (en) | 2013-03-10 | 2014-09-18 | Peritech Pharma Ltd. | Topical compositions and methods of treatment of topical disorders |
| WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2016022462A1 (en) * | 2014-08-04 | 2016-02-11 | University Of Georgia Research Foundation Inc. | Therapeutic nanoparticles for accumulation in the brain |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| DK3261640T3 (da) | 2015-02-25 | 2022-07-11 | Univ California | 5ht-agonister til behandling af epilepsilidelser |
| EP3268086A4 (en) | 2015-03-10 | 2018-11-07 | Eleusis Benefit Corporation, PBC | Lsd for the treatment of alzheimer's disease |
| EP4173550A1 (en) | 2015-03-16 | 2023-05-03 | Magic Leap, Inc. | Diagnosing and treating health ailments |
| US10664572B2 (en) | 2015-08-06 | 2020-05-26 | Microsoft Technology Licensing, Llc | Recommendations for health benefit resources |
| TW201822139A (zh) | 2016-07-29 | 2018-06-16 | 嘉康利公司 | 用於動態產生個人的健康相關且客製化的建議之技術 |
| US20190311789A1 (en) * | 2016-10-03 | 2019-10-10 | West Virginia University | Computer implemented discovery of biomarkers for blood brain barrier disruption |
| US10596378B2 (en) | 2016-10-18 | 2020-03-24 | Joseph Rustick | Method for treatment of depression using synaptic pathway training |
| NL2018190B1 (en) | 2017-01-18 | 2018-07-26 | Procare Beheer B V | Psilocybin or psilocin in combination with cannabinoid |
| JP7273731B2 (ja) | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| US20190142851A1 (en) | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| CN108619214A (zh) * | 2017-03-15 | 2018-10-09 | 王慎君 | 一种治疗肿瘤的药物 |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2019079742A1 (en) | 2017-10-19 | 2019-04-25 | Eleusis Benefit Corporation, Pbc | METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES |
| WO2019161050A1 (en) | 2018-02-18 | 2019-08-22 | Akili Interactive Labs, Inc. | Cognitive platform including computerized elements coupled with a therapy for mood disorder |
| FI129102B (en) | 2018-03-19 | 2021-07-15 | Teknologian Tutkimuskeskus Vtt Oy | Heterological production of psilosybin |
| EP3813810A4 (en) | 2018-06-21 | 2022-03-30 | Robert John Petcavich | METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| EP3675137A1 (en) | 2018-12-27 | 2020-07-01 | Telefonica Innovacion Alpha S.L | Method and system for more efficient wellbeing estimation and improvement |
| CA3125439A1 (en) | 2019-01-04 | 2020-07-09 | Apollo Neuroscience, Inc. | Systems and methods of wave generation for transcutaneous vibration |
| MX2021009037A (es) * | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| WO2021003467A1 (en) | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| US11766445B2 (en) | 2019-07-18 | 2023-09-26 | Concept Matrix Solutions | Oral soft gel capsule containing psychedelic compound |
| GB201911024D0 (en) | 2019-08-01 | 2019-09-18 | Beckley Found | Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders |
| GB201911095D0 (en) | 2019-08-02 | 2019-09-18 | Randox Laboratories Ltd | Biological status classification |
| WO2021030571A1 (en) | 2019-08-13 | 2021-02-18 | University Of Maryland, Baltimore | Methods of treating psychological and brain disorders |
| JP2022549488A (ja) | 2019-09-25 | 2022-11-25 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 投与量レジメン及び構成成分の互換性を確立するための薬物投与デバイス及びシステム |
| WO2021072530A1 (en) | 2019-10-15 | 2021-04-22 | Tassili Life Sciences, Corp. | Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder. |
| US20230021957A1 (en) | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| US20210236523A1 (en) | 2020-02-05 | 2021-08-05 | Yale University | Psychedelic treatment for headache disorders |
| IL295671A (en) | 2020-02-28 | 2022-10-01 | Universit?Tsspital Basel | Controlling effects after 5ht2a agonists administration |
| CN115916173A (zh) | 2020-04-13 | 2023-04-04 | 巴塞尔大学医院 | Lsd剂量鉴定 |
| AU2021267101B2 (en) | 2020-05-05 | 2024-03-28 | Universitätsspital Basel | MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics |
| AU2021292943B2 (en) | 2020-06-15 | 2024-04-04 | Universitätsspital Basel | MDMA response prediction |
| AU2021311493A1 (en) | 2020-07-24 | 2023-03-16 | Mindset Pharma Inc. | Scalable synthetic route for psilocin and psilocybin |
| EP4188382A4 (en) | 2020-07-29 | 2024-08-14 | The Royal Institution for the Advancement of Learning / McGill University | Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions |
| WO2022023812A1 (en) | 2020-07-29 | 2022-02-03 | Diamond Therapeutics Inc. | Extended release 5-ht receptor agonists for neurological conditions |
| CA3188263A1 (en) | 2020-08-05 | 2022-02-10 | Matthias Emanuel LIECHTI | Intravenous dmt administration method for dmt-assisted psychotherapy |
| AU2021382158C1 (en) | 2020-11-18 | 2026-05-07 | Definium Therapeutics US, Inc. | Mdma prodrugs to assist psychotherapy |
| US20220273628A1 (en) | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| US20220267252A1 (en) | 2021-02-24 | 2022-08-25 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
| US20220265582A1 (en) | 2021-02-24 | 2022-08-25 | Universitätsspital Basel | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy |
| BR112023017866A2 (pt) | 2021-03-06 | 2023-10-10 | Univ Basel | Método de dosagem de lsd no tratamento de pacientes, método para determinar uma dose preferida de lsd e método para determinar uma dose de lsd com base na avaliação da presença de inibidores de cyp2d6 |
| EP4304603A4 (en) | 2021-03-08 | 2025-01-22 | Diamond Therapeutics Inc. | 5-ht receptor agonist titration |
| CN117177959A (zh) | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | 裸头草碱类似物、盐、组合物和使用方法 |
| US20220323405A1 (en) | 2021-04-08 | 2022-10-13 | Universitätsspital Basel | Combination product using 3,4-methylenedioxymethamphetamine and carvedilol for the treatment of psychiatric disorders |
| EP4792879A2 (en) | 2021-05-17 | 2026-08-19 | Cybin IRL Limited | Formulations of psilocybin |
| US11801256B2 (en) | 2021-06-08 | 2023-10-31 | Universitätsspital Basel | Antidepressant-psilocybin co-treatment to assist psychotherapy |
| WO2023012524A2 (en) | 2021-08-03 | 2023-02-09 | Universitatsspital Basel | Lsd and psilocybin dose equivalence determination |
| EP4392402A4 (en) | 2021-08-24 | 2025-07-09 | Mind Medicine Inc | SYNTHETIC PATHWAYS TO ACCESS MDMA PRODRUGS USING CONTROLLED AND UNCONTROLLED INTERMEDIATES |
| CA3133547C (en) | 2021-10-07 | 2024-07-02 | Psilo Scientific Ltd. | LIQUID-LIQUID EXTRACTION OF PURIFIED PSYCHOACTIVE ALKALOIDS |
| US20230233688A1 (en) | 2021-11-04 | 2023-07-27 | Mind Medicine, Inc. | Mdma prodrugs to assist psychotherapy |
| WO2023091437A1 (en) | 2021-11-17 | 2023-05-25 | Mind Medicine, Inc. | Desoxyscaline derivatives with modified mescaline-like action |
| US20230285327A1 (en) | 2021-11-17 | 2023-09-14 | Mind Medicine, Inc. | Desoxyscaline derivatives with modified mescaline-like action |
| CA3242786A1 (en) | 2022-01-07 | 2023-07-13 | Universitatsspital Basel | R-MDMA AND S-MDMA TO AID PSYCHOTHERAPY |
| US20240307345A1 (en) | 2022-01-07 | 2024-09-19 | Universitatsspital Basel | R-MDMA and S-MDMA TO ASSIST PSYCHOTHERAPY |
| US20250182901A1 (en) | 2022-03-07 | 2025-06-05 | Diamond Therapeutics Inc. | Systems and methods for affecting well-being |
| US20250176904A1 (en) | 2022-05-23 | 2025-06-05 | Diamond Therapeutics Inc. | Pre-dosing method of assessing drug benefits in patients |
| CA3247344A1 (en) | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| CN119923261A (zh) | 2022-06-20 | 2025-05-02 | 思维医学股份有限公司 | 具有改良的lsd样作用的麦角酸衍生物 |
| WO2024118280A1 (en) | 2022-11-30 | 2024-06-06 | Mind Medicine, Inc. | 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action |
| WO2024263978A1 (en) | 2023-06-22 | 2024-12-26 | Mind Medicine, Inc. | Allyl- and propargylamine-type phenethylamines and tryptamines for treating medical disorders |
-
2020
- 2020-01-29 MX MX2021009037A patent/MX2021009037A/es unknown
- 2020-01-29 CA CA3127854A patent/CA3127854A1/en active Pending
- 2020-01-29 WO PCT/IB2020/000052 patent/WO2020157569A1/en not_active Ceased
- 2020-01-29 AU AU2020215150A patent/AU2020215150B8/en active Active
- 2020-01-29 EP EP20748736.4A patent/EP3917537A4/en active Pending
- 2020-01-29 KR KR1020217026762A patent/KR20210134313A/ko not_active Ceased
- 2020-01-29 BR BR112021014750-0A patent/BR112021014750A2/pt unknown
- 2020-01-29 JP JP2021543489A patent/JP2022523700A/ja active Pending
- 2020-01-29 MA MA054877A patent/MA54877A/fr unknown
- 2020-01-29 CN CN202080027002.3A patent/CN114040767A/zh active Pending
- 2020-01-29 US US17/427,037 patent/US20220096504A1/en not_active Abandoned
-
2021
- 2021-07-27 MX MX2025007468A patent/MX2025007468A/es unknown
- 2021-07-28 IL IL285186A patent/IL285186A/en unknown
-
2022
- 2022-11-08 US US18/053,648 patent/US20230113351A1/en not_active Abandoned
-
2024
- 2024-08-22 US US18/812,847 patent/US20260053829A1/en active Pending
- 2024-08-23 US US18/814,163 patent/US12691130B2/en active Active
-
2025
- 2025-04-30 AU AU2025203049A patent/AU2025203049A1/en active Pending
- 2025-08-14 JP JP2025135216A patent/JP2025186241A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
Non-Patent Citations (4)
| Title |
|---|
| CARHART-HARRIS ET AL.: "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study", LANCET PSYCHIATRY, vol. 3, no. 7, 17 May 2016 (2016-05-17), pages 619 - 627, XP055708476 * |
| ERRITZOE D ET AL: "Effects of psilocybin therapy on personality structure", ACTA PSYCHIATRICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DE, vol. 138, no. 5, 19 June 2018 (2018-06-19), pages 368 - 378, DOI: 10.1111/ACPS.12904 * |
| GRIFFITHS "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial", JOURNAL OF PSYCHOPHARMACOLOGY, vol. 30, no. 12, 2016, pages 1181 - 1197 * |
| MORENO FRANCISCO A ET AL: "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder", THE JOURNAL OF CLINICAL PSYCHIATRY, USA, vol. 67, no. 11, (2006), pages 1735 - 1740, DOI: 10.4088/JCP.V67N1110 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022523700A (ja) | 2022-04-26 |
| IL285186A (en) | 2021-09-30 |
| AU2020215150A1 (en) | 2021-09-09 |
| AU2025203049A1 (en) | 2025-05-22 |
| CN114040767A (zh) | 2022-02-11 |
| KR20210134313A (ko) | 2021-11-09 |
| MA54877A (fr) | 2021-12-08 |
| WO2020157569A1 (en) | 2020-08-06 |
| US12691130B2 (en) | 2026-07-28 |
| US20230113351A1 (en) | 2023-04-13 |
| AU2020215150A8 (en) | 2025-07-03 |
| MX2021009037A (es) | 2021-10-13 |
| MX2025007468A (es) | 2025-07-01 |
| AU2020215150B2 (en) | 2025-02-06 |
| EP3917537A1 (en) | 2021-12-08 |
| EP3917537A4 (en) | 2022-09-07 |
| US20260053831A1 (en) | 2026-02-26 |
| US20220096504A1 (en) | 2022-03-31 |
| US20260053829A1 (en) | 2026-02-26 |
| CA3127854A1 (en) | 2020-08-06 |
| BR112021014750A2 (pt) | 2021-09-28 |
| JP2025186241A (ja) | 2025-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260053831A1 (en) | Compositions and methods for improving cognitive function | |
| US20230233584A1 (en) | Extended release 5-ht receptor agonists for neurological conditions | |
| JP7801518B2 (ja) | 新規な組成物および医薬組成物 | |
| US20250197397A1 (en) | Organic compounds | |
| TWI692465B (zh) | 酚系trpv1促效劑之前藥 | |
| CN108042808A (zh) | 用于治疗中枢系统疾病的包含依匹哌唑或其盐和第二种药物的组合 | |
| JP2013544230A (ja) | 口腔内分散性製剤 | |
| EP2079449A2 (en) | Phenylalkylamino carbamate compositions | |
| CN110234636A (zh) | 包含哌醋甲酯前药的组合物,其制造和使用方法 | |
| WO2025111482A1 (en) | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios | |
| TW202423415A (zh) | N-n-二甲基色胺(dmt)及dmt類似物組合物、其製造方法及使用方法 | |
| KR20050009983A (ko) | 트라마돌의 서방성 제제 | |
| US20260053832A1 (en) | Compositions and methods for improving cognitive function | |
| US20260053830A1 (en) | Compositions and methods for improving cognitive function | |
| WO2012129232A1 (en) | Compositions for the treatment of psychotic or neurological disorders | |
| CN106177962A (zh) | 含沙格雷酯的药物组合物用于治疗或预防脂肪肝、肝纤维化和/或肝损伤的用途 | |
| JP2026513655A (ja) | フェネチルアミン化合物、組成物、及び使用方法 | |
| US11858908B2 (en) | Compositions and methods for inhibiting IDO1 | |
| EP3860599A1 (en) | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders | |
| WO2023224960A1 (en) | Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use | |
| US20150238615A1 (en) | Denaturants for sympathomimetic amines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 35 , NO 36 , PAGE(S) 7264 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME DIAMOND THERAPEUTICS INC, APPLICATION NO. 2020215150, UNDER INID (71) CORRECT THE APPLICANT NAME TO DIAMOND THERAPEUTICS INC. Free format text: IN VOL 59 , NO 6 , PAGE(S) 803 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME DIAMOND THERAPEUTICS INC, APPLICATION NO. 2020215150, UNDER INID (71) CORRECT THE APPLICANT NAME TO DIAMOND THERAPEUTICS INC. |